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Abstract
Background: Arduous to differ clinically, extrapulmonary tuberculosis and focal complications of brucellosis remain
important causes of morbidity and mortality in many countries. We developed and applied a multiplex real-time PCR assay
(M RT-PCR) for the simultaneous detection of Mycobacterium tuberculosis complex and Brucella spp.
Methodology: Conventional microbiological techniques and M RT-PCR for M. tuberculosis complex and Brucella spp were
performed on 45 clinical specimens from patients with focal complications of brucellosis or extrapulmonary tuberculosis
and 26 control samples. Fragments of 207 bp and 164 bp from the conserved region of the genes coding for an
immunogenic membrane protein of 31 kDa of B. abortus (BCSP31) and the intergenic region SenX3-RegX3 were used for
the identification of Brucella and M. tuberculosis complex, respectively.
Conclusions: The detection limit of the M RT-PCR was 2 genomes per reaction for both pathogens and the intra- and inter-
assay coefficients of variation were 0.44% and 0.93% for Brucella and 0.58% and 1.12% for Mycobacterium. M RT-PCR
correctly identified 42 of the 45 samples from patients with tuberculosis or brucellosis and was negative in all the controls.
Thus, the overall sensitivity, specificity, PPV and NPV values of the M RT PCR assay were 93.3%, 100%, 100% and 89.7%,
respectively, with an accuracy of 95.8% (95% CI, 91.1%–100%). Since M RT-PCR is highly reproducible and more rapid and
sensitive than conventional microbiological tests, this technique could be a promising and practical approach for the
differential diagnosis between extrapulmonary tuberculosis and focal complications of brucellosis.
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Introduction
The global burden of tuberculosis remains enormous and
brucellosis continues to be the most common zoonotic infection
worldwide, representing a major source of human disease[1–2]. Both
tuberculosis and brucellosis are granulomatous diseases with great
clinical polymorphism. Extrapulmonary forms account for 10% to
40% of all cases of tuberculosis [3–4] and focal complications are
present in 20% to 40% of brucellosis patients [5–6]. Extrapulmonary
tuberculosis and focal forms of brucellosis have been described in
almost all organs and systems, with osteoarticular, genitourinary,
hepatic or central nervous system involvement being frequent in both
diseases [4–5]. Accordingly, in areas of high incidence, a differential
diagnosis between both processes is often necessary [7].
Culture remains the gold standard for the diagnosis of
tuberculosis and brucellosis. However, as both Brucella spp and
Mycobacterium tuberculosis are slowly growing pathogens, cultures are
labor intensive, which can at times lead to unacceptable delays in
diagnosis. Furthermore, cultures can be very insensitive in some
cases of extrapulmonary tuberculosis and focal forms of brucellosis
[8–9]. To overcome certain limitations of conventional microbi-
ological techniques, PCR-based assays may be useful for the
diagnosis of both tuberculosis and human brucellosis [10–11]. The
use of real-time PCR technology reduces the time to identification
of bacterial DNA directly from clinical samples. Additionally,
considerable time and effort can be saved by simultaneously
amplifying multiple sequences in a single reaction. This strategy,
named Multiplex PCR, has proven to be very useful in different
clinical scenarios [12–13].
The aim of this study was to develop a multiplex real-time PCR
(M RT-PCR) assay to simultaneously detect Brucella spp and M.
tuberculosis complex DNA and analyze its yield in the rapid
differential diagnosis between extrapulmonary tuberculosis and
certain focal complications of brucellosis.
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Bacteria species and strains
The strains of Brucella used in this study were supplied by the
Microbiology Department of the Faculty of Medicine at Valladolid
University, except for the vaccine strains B-19 and Rev-1, kindly
provided by the Agriculture Department of the Andalusian
Regional Government. These strains were cultured on Brucella
agar (Difco, USA) and incubated at 37uC with 5% CO2 for 48 h.
All non-tuberculous mycobacteria strains except M. avium and M.
celatum were provided by the Coleccio ´n Espan ˜ola de Cultivos Tipo
(CECT) (Valencia, Spain). These strains were grown on Low-
enstein-Jensen medium (Biomedics, Spain) at 37uC for 2–4 weeks.
Study population
Forty-five non-blood clinical specimens from 25 patients with
different focal complications of brucellosis and 18 patients with
extrapulmonary tuberculosis were studied by M RT-PCR assay.
One brucellosis patient who had two different focal complications
and another with tuberculous spondylitis and therapeutic failure
each provided two different samples.
The samples came from vertebral or other bone tissue (13
patients), lymph nodes (7 patients), tissue or pus from hepato-
splenic abscesses (6 patients), cerebrospinal fluid (CSF) (5 patients),
synovial fluid (4 patients), urine or kidney tissue (4 patients), pleural
fluid (3 patients), pericardial tissue (2 patients) and thyroid tissue (1
patient).
Control samples were obtained from 26 patients with other
disorders initially involving a differential diagnosis with extrapul-
monary tuberculosis or brucellosis: pyogenic hepatosplenic
abscesses (7 patients), septic arthritis (6 patients), pyogenic
vertebral osteomyelitis (6 patients), bacterial meningitis (3 patients)
and non-tuberculous vertebral osteomyelitis, hepatic Hodgkin
lymphoma, kidney abscess and pyogenic pericarditis (1 each).
The diagnosis of brucellosis was established according to one of
the following criteria: first, isolation of Brucella spp. from blood or
any other body fluid or tissue sample or second, the presence of a
compatible clinical picture together with the demonstration of
specific antibodies at significant titers or seroconversion. Signifi-
cant titers were considered to be a standard tube agglutination test
(SAT) titer of $1/160 or an immunocapture agglutination test
$1/320. The diagnosis of tuberculosis was based on isolation of
M. tuberculosis or the presence of caseating granulomas, with or
without acid-fast bacilli, in a patient with a compatible clinical
picture and good therapeutic response to antituberculous treat-
ment.
Ethics Statement. All patients provided written informed
consent prior to the collection of biological samples. The
utilization of samples for research purposes was approved by the
Ethical Committee of Carlos Haya University Hospital, Malaga,
Spain.
Microbiological studies
Two blood cultures were performed for all patients with
suspected brucellosis. Blood samples were incubated in a non-
radiometric semiautomatic BACTEC 9240 system (Becton Dick-
inson, Diagnostic Instrument Systems, Sparks, MD), and pro-
cessed according to usual techniques. All isolates were identified
according to normalized protocols [14].
All non-blood samples were stained with Gram, Ziehl–Neelsen
and auramine and cultured onto blood and chocolate agar media,
MacConkey agar, Brucella agar Lowenstein–Jensen and/or Mid-
dlebrook medium (BACTEC MGIT 960, Becton Dickinson,
Diagnostic Systems, Spark, MD). SAT was performed as described
[15] and immunocapture-agglutination test (Brucellacapt; Vircell
SL, Sante Fe ´, Granada) was done following the manufacturer’s
instructions [16].
DNA extraction
All samples destined for M RT-PCR were maintained at
220uC until processing. The volume varied depending on the type
of sample. DNA was extracted using the UltraClean Tissue DNA
isolation Kit (Mo Bio Laboratories). Prior to DNA extraction,
homogenized samples from the different tissues, CSF, synovial or
pleural fluid and purulent sample collections were resuspended in
1 ml of molecular biology water, mixed and centrifuged at
150006g for 5 min. The supernatant was discarded and the pellet
was resuspended with the volume of buffer outlined in the
manufacturer’s instructions. DNA pellets were resuspended in
50 ml molecular biology water and stored at 4uC until use.
Aliquots of 5 ml of the suspension (template DNA) were used for
PCR analysis. To monitor contamination, negative controls were
included during each DNA extraction procedure.
Real-time PCR primers and probes
For the detection of Brucella spp, a 207 bp fragment from the
conserved region of the gene which encodes an immunogenic
membrane protein of 31 kDa of B. abortus (BCSP31) specific to the
Brucella genus and present in all its biovars was amplified using the
primers B1 and B2. Primers M1 and M3 amplifying a sequence of
164 bp based on the intergenic region of the genes coding for a
mycobacterial two-component system SenX3-RegX3 were used
for the identification of M. tuberculosis complex. This DNA target
sequence is present in all strains of M. tuberculosis complex and is
absent from all other non-tuberculous mycobacterial strains. The
sequences and positions of the amplification primers and the
detection probes are shown in Table 1. Fluorescent hybridization
probes were designed to anneal within the gene fragment
generated by amplification of the corresponding target. The
Brucella hybridization probe set (SB1 and SB2) was fluorescein- and
LCRed640-labeled and the M. tuberculosis complex hybridization
probe set (SM1 and SM3) was fluorescein-and LCRed705-labeled.
An extensive search of several databases, including EMBL and
GenBank databases, indicated that neither the primers nor the
probes shared significant homology with any known nucleotide
sequence. All primers and probes were synthesized by Proligo
(Sigma Aldrich).
Real-time PCR assay conditions
Amplification and melt curve analysis were performed using a
LightCycler (Roche Diagnostics, Indianapolis, IN). Reactions were
carried out in a total volume of 20 ml. PCR mixes contained
primers and probes at final concentrations of 0.6 mM and 0.2 mM,
respectively. FastStart DNA Master Hybridization Probes kit
(Roche Molecular Biochemicals, Mannheim, Germany) was used;
4 ml of the master mixture and 5 ml of DNA samples were loaded
into glass capillary tubes. After a short centrifugation (30006g for
10 s) the sealed capillaries were placed into the LightCycler rotor.
After an initial polymerase activation and denaturation step at
95uC for 10 min, the samples ran 45 amplification cycles, each
comprising denaturation (95uC for 10 s), annealing (60uC for
20 s), and extension (72uC for 10 s) in the LightCycler 2.0, with a
temperature transition rate of 20uC/s for all steps. After
completion, a melting curve was recorded by heating to 95uC
for 0 s at 20uC/s, holding at 41uC for 20 s at 20uC/s, and then
heating slowly at 0.1uC/s until 85uC. A final cooling step of 40uC
for 15 s was added. The peak melting temperature obtained
represented the specific amplified product. Each product was
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generated by the BCSP31 product was measured at 640 nm and
the SenX3-RegX3 intergenic region product signal was measured
at 705 nm following 60uC, 20 s annealing incubation.
A compensation data file was created using the LightCycler-
Color Compensation Set (Roche Diagnostic, Indianapolis, IN).
Fluorescence curves were analyzed with the LightCycler software
v. 4.0. To minimize experimental variability, we used the
automated second derivate maximum estimation method to
determine the amplification crossing point (Cp or threshold cycle)
that marked the cycle at which fluorescence of the sample became
significantly different from the baseline signal.
Positive controls, included in all tests, comprised serial dilutions
of B. abortus B-19 and M. tuberculosis DNA. Negative controls were
also included and contained all the elements of the reaction
mixture except template DNA. To guarantee the reliability of the
results, all samples were processed in duplicate. A sample was
defined as positive only when the Cp value was #36 cycles in both
replicates and the melting temperature peak was consistent with
that produced by the corresponding positive controls. The absence
of an amplification curve or a Cp value $37 cycles was considered
to indicate a negative sample.
Universal precautions and one-way flow of DNA extraction and
amplification were used to prevent contamination. To avoid
potential observer bias, the status of each patient for Brucella and
Mycobacterium infection was unknown during the PCR assay.
Sequencing of M RT-PCR product
To confirm the identities of the amplified fragments, the M RT-
PCR products for Brucella spp and M. tuberculosis complex were
sequenced. The ABI PRISM Big Dye Terminator Cycle
sequencing reaction kit v. 3.0 (Applied Biosystems, Madrid, Spain)
was used for the sequencing reactions. Sequence analysis was by
capillary electrophoresis in an ABI PRISM, model 3100
automated sequencer (Applied Biosystems).
Statistical Analysis
Sensitivity, specificity, positive and negative predictive values,
accuracy, likelihood ratios (LR) and 95% confidence intervals (CI)
were calculated using the Twobytwo 1.0 analyzer program.
Results
Analytical sensitivity
The M RT-PCR analytical sensitivity was initially determined
by amplifying ten-fold serial dilutions of DNA from B. abortus B-19
and M. caprae. The detection limit was 2610
0 genomes per
reaction for both pathogens. The assays showed a linear
quantitative range over five orders of magnitude from 2610
5
down to 2610
0 genomes per reaction, with linear regression
equations of Cp=23.37 log (genome number.) +36.92 and
Cp=23.32 log (genome number.) +36.89, correlation coefficients
(R
2) values of 0.99 and a PCR efficiencies (E) of 2.0 for Brucella and
Mycobacterium respectively.
Reproducibility
Intra-assay variability was determined by amplifying, in
quadruplicate, dilutions of DNA from B. abortus B-19 and M.
caprae, equivalent to 2610
4 to 2610
0 copies per reaction.
Threshold cycle values (Cp) obtained for the same dilutions on
five different days were used to determine the inter-assay
variability. The mean coefficients of variation (CV) for intra-assay
repetitions were 0.44% for Brucella and 0.58% for M. tuberculosis
complex, with CV values of 0.32%, 0.74%, 0.35%, 0.35% and
0.35%, 0.63%, 0.65%, 0.69% for the samples with 2610
4,2 610
3,
2610
1,2 610
0 copies per reaction of Brucella and Mycobacterium,
respectively. The mean inter-assay CVs for the whole group of
samples were 0.93% for Brucella and 1.12% for Mycobacterium with
CV values of 0.73%, 0.80% 0.66%, 1.14% and 1.09%, 0.91%,
1.21%, 1.29% for the samples with 2610
4,2 610
3,2 610
1,2 610
0
copies per reaction of Brucella and Mycobacterium, respectively.
Specificity
To confirm the specificity, we tested different strains of Brucella,
M. tuberculosis complex and non-tuberculous Mycobacteria
(Table 2). Only amplified fragments from M. tuberculosis complex
were detected at a wavelength of 705 nm, indicating the
fluorogenic probes were specific for M. tuberculosis complex and
did not cross-react with Brucella spp or other non-tuberculous
Mycobacteria strains. Fluorescent signals at 640 nm were obtained
with all strains of Brucella spp assayed but not with any
Mycobacterium strain (Figure 1). The M RT-PCR assay was
therefore 100% specific.
Clinical sensitivity and specificity
Of the 25 brucellosis patients, diagnosis was established by
isolating the pathogen in blood cultures or in cultures of other
samples in 17 cases (68%). For the remaining 8 patients (32%), the
diagnosis was made by clinical-serological means. All the strains
isolated were identified as B. melitensis. Brucella was isolated in non-
blood samples in seven patients (26.9%) (two with vertebral
Table 1. Nucleotide sequences and positions of primers and probes for amplification and detection of Brucella spp. and M.
tuberculosis complex for M RT-PCR.
Oligonucleotide Sequence Position Product Length (bp)
B1 up 59-ggctcggttgccaatatcaat-39 788-810
B2 down 59-gtctgcgaccgatttgatgt-39 995-977 207
SB1 FL probe 59-aggcaacgtctgactgcgtaaagcc -FL-39 862-838
SB2 Red probe 59-Red 640 -actccagagcgcccgacttgatcg-Phos-39 835-812
M1 up 59-cggctaatcacgacggcac -39 1114-1132
M3 down 59-ctcttcctctcgttgtgacctgtt-39 1277-1254 164
SM1 FL probe 59-tggctcttccggcgttgatcgag- FL-39 1177-1199
SM3 Red probe 59-Red 705-cctatcacgacgacgagcgacccga-Phos-39 1225-1201
Red 640- LightCycler Red 640, Red 705- LightCycler Red 705, FL-5,6-carboxifluoresceı ´na.
doi:10.1371/journal.pone.0004526.t001
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abscess, knee arthritis and thyroid abscess). M RT-PCR identified
Brucella DNA in 25 (96.1%) of the 26 samples. The patient with a
false-negative M RT-PCR experienced a relapse of knee arthritis
and from whom B. melitensis was isolated in synovial fluid.
Of the 19 samples obtained from patients with tuberculosis, AFB
smears were positive in 9 (52.9%) of the 17 cases in which the test
was carried out, culture was positive in 14 (73.7%) cases and M RT-
PCR assay was positive in 17 (89.5%) cases. The two negative M
RT-PCR results corresponded to one patient with tuberculous
Table 2. Multiplex PCR results with DNA from different Brucella and Mycobacterium strains.
Species Biovar Strain Origin M tuberculosis complex Brucella
Brucella melitensis 1 16 M FMV 2 +
Brucella melitensis 1 Rev 1 CAJA 2 +
Brucella melitensis 26 3 / 9 F M V 2 +
Brucella melitensis 3 Ether FMV 2 +
Brucella melitensis 2 (clinical strain) FMV 2 +
Brucella melitensis 3 (clinical strain) FMV 2 +
Brucella abortus 1 (clinical strain) FMV 2 +
Brucella abortus 1 B19 CAJA 2 +
Brucella abortus 2 86/8/59 FMV 2 +
Brucella abortus 3 Tulya FMV 2 +
Brucella abortus 4 292 FMV 2 +
Brucella abortus 5 B3196 FMV 2 +
Brucella abortus 6 870 FMV 2 +
Brucella abortus 7 63/75 FMV 2 +
Brucella abortus 9 C/68 FMV 2 +
Brucella suis 1 10036 FMV 2 +
Brucella suis 2 10510 FMV 2 +
Brucella suis 3 10511 FMV 2 +
Brucella suis 44 0 F M V 2 +
Brucella suis 5 10980 FMV 2 +
Brucella neotomae 10084 FMV 2 +
Brucella ovis Reo198 FMV 2 +
Brucella canis 10854 FMV 2 +
Mycobacterium tuberculosis 1100 HCH + 2
Mycobacterium caprae 1040 HCH + 2
Mycobacterium africanum 1031 HCH + 2
Mycobacterium bovis 530 HCH + 2
Mycobacterium avium 1062 ATCC 22
Mycobacterium xenopi 1071 HCH 22
Mycobacterium kansasii 1085 HCH 22
Mycobacterium chelonae 1052 HCH 22
Mycobacterium gordonae 953 HCH 22
Mycobacterium fortuitum 944 HCH 22
Mycobacterium scrofulaceum 702 HCH 22
Mycobacterium szulgai CC 1/07 HCH 22
Mycobacterium marinum 7091 CECT 22
Mycobacterium celatum 342 ATCC 22
Mycobacterium intracellulare CC 2/04 HCH 22
Mycobacterium simiae 946 HCH 22
Mycobacterium smegmatis 3017 CECT 22
Mycobacterium flavencens 3027 CECT 22
Mycobacterium Phlei CECT 22
FMV, Facultad de Medicina Valladolid, Valladolid, Spain; CAJA, Consejeria de Agricultura, Junta de Andalucia, Seville, Spain; CECT, Coleccio ´n Espan ˜ola de Cultivos Tipo,
Valencia, Spain; HCH, Hospital Carlos Haya, Ma ´laga, Spain. ATCC, American Type Culture Collection.
doi:10.1371/journal.pone.0004526.t002
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ankle arthritis from which M. tuberculosis was isolated in culture.
M RT-PCR was negative in all the controls, including one with
HIV and vertebral osteomyelitis due to M. xenopi.
Considering the patients with tuberculosis and brucellosis
together, the sensitivity, specificity, PPV and NPV values of our
M RT PCR assay were 93.3%, 100%, 100% and 89.7%,
respectively, with an accuracy of 95.8% (95% CI, 91.1%–100%)
and a negative LR of 0.07 (95% CI, 0.02–0.2) (Table 3).
The mean Cp was 29.364.6 cycles in the patients with Brucella
and 30.565.5 cycles for those with tuberculosis. In both cases
melting temperature analysis confirmed the nature of the
amplified product (Figure 2).
The M RT-PCR results were similar when an identical panel of
samples was assayed in a double-tube format (Figure 3).
Discussion
Traditional laboratory techniques for the diagnosis of tubercu-
losis and brucellosis are far from being sensitive and specific. In the
case of tuberculosis, direct microscopy lacks sensitivity and
serological diagnosis of brucellosis lacks adequate specificity.
Moreover, in both cases, cultures are time consuming and require
direct sample handling, representing a risk of infection for
laboratory personnel.
Figure 1. Agarose gel electrophoresis and ethidium bromide staining. Lanes: MW, molecular size DNA ladder XIII; 1, positive control (M.
caprae); 2 to 3, DNA from two strains of M. tuberculosis complex (M. tuberculosis and M. africanum); 4 to 6, samples of pleural fluid, psoas abscess and
urine, respectively, from three patients with tuberculosis; 7, no ADN added; 8 positive control (B. Melitensis Rev-1); 9 to 10, DNA from hepatic abscess
and kidney tissue, respectively, from two patients with brucellosis.
doi:10.1371/journal.pone.0004526.g001
Table 3. Diagnostic yield of Multiplex real-Time PCR in clinical specimens from patients with extrapulmonary tuberculosis and
focal complications of brucellosis.
All samples Samples from patients with focal Brucellosis Samples from patients with extrapulmonary TBC
N=45 N=26 N=19
%, (95% CI)
Sensitivity 93.3, (86–100) 96.2, (88.8–100) 89.5, (75.7–100)
Specificity 100 100 100
PPV 100 100 100
NPV 89.7, (78.6–100) 97.8, (93.6–100) 96.3, (91.3–100)
Accuracy 95.8, (91.1–100) 98.6, (95.9–100) 97.2, (93.3–100)
Positive LR ND
a ND
a ND
a
Negative LR 0.07, 0.02–0.20 0.04, 0.01–0.26 0.11, 0.03–0.39
PPV=positive predictive value; NPV=negative predictive value; Positive LR=positive likelihood ratio, Negative LR=negative likelihood ratio.
anot done for mathematical reasons (division by zero).
doi:10.1371/journal.pone.0004526.t003
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Molecular techniques have proven more sensitive than conven-
tional methods in both tuberculosis and human brucellosis [10–
11,17–20]. Real-time PCR technology has provided an opportu-
nity to develop an assay that meets the requirements for rapid
diagnosis, thus increasing the interest of clinical laboratories in
molecular diagnosis [21].
Multiplex polymerase chain reaction is a variant of PCRin which
two or more target sequences can be simultaneously amplified.
Multiplex PCR has the potential to produce considerable savings in
time and effort in the laboratory. This method has been successfully
applied in many areas of DNA testing, including the field of
infectious diseases [22]. From a clinical and microbiological point of
view, multiplex PCR would be specially useful in those scenarios in
which several agents cause similar clinical syndromes.
Numerous PCR assays employing a number of different M.
tuberculosis and Brucella spp targets have recently been described
[23–24]. For the detection of Brucella, we chose a conserved region
of the gene encoding for BCSP31, the target with the most clinical
experience [11,25–26]. For tuberculosis, we opted for specificity.
The IS6110 multicopy insertion element, the most widely used
target sequence of the M. tuberculosis genome, does not allow
specific identification of M. tuberculosis [27]. Moreover, M.
tuberculosis strains lacking the IS6110 element have been described
[28]. Accordingly, we selected a sequence of the SenX3-RegX3
intergenic region (IR) which contains mycobacterial interspersed
repetitive units (MIRUs), described only for mycobacterial species
belonging to the M. tuberculosis complex [29–30].
Our results demonstrate the specificity of M RT-PCR. All the
strains of Brucella spp and M. tuberculosis complex showed clear DNA
amplification, confirmed by melting curve analysis and sequencing
the amplified products, which perfectly matched the 207 bp and
164 bp fragments corresponding to B. abortus and the SenX3-RegX3
intergenic region of M. tuberculosis complex. No cross-reaction
occurred with any of the strains of the wide panel of non-tuberculous
micobacteria tested. These results agree with those of Broccolo et al
[29] and appear to confirm that the amplification of a DNA fragment
belonging to the SenX3-RegX3 IR is very specific and allows for a
more precise identification of the M. tuberculosis complex species.
Under the conditions used, the precision of our M RT-PCR can
be considered very high, as the intra-assay variation was lower
than 1% and the inter-assay variation around 2%. Bearing in
mind that the inoculum found in clinical samples from patients
with extrapulmonary tuberculosis or focal complications of
brucellosis could be very small, the detection capacity of any
multiplex PCR assay used in these diagnoses needs to be very high.
The analytical sensitivity of our M RT-PCR, 2 genome
equivalents, can also be considered very good, as it is similar or
higher than that of conventional PCR procedures previously used
for the diagnosis of tuberculosis or brucellosis. Such small amounts
of DNA can be expected in any clinical sample from a patient with
active extrapulmonary tuberculosis or focal brucellosis.
Numerous studies have assessed the yield of PCR techniques for
the diagnosis of extrapulmonary tuberculosis [10,18–20] and a few
others for focal complications of brucellosis [11,17]. Nevertheless,
this is the first study designed to verify the usefulness of multiplex
technology applied to the rapid differential diagnosis between
extrapulmonary tuberculosis and focal complications of brucello-
sis. Overall, the sensitivity and specificity of our M RT-PCR were
very high, correctly identifying 93.3% of the patients with
tuberculosis or brucellosis, and showing negative in all the
controls. Individually, the sensitivity in the diagnosis of patients
with focal complications of brucellosis was 96.2%, similar to that
reported for an in-house PCR assay [11] and far better than
culture, for which positivity was again shown to be below 50%.
The sensitivity in clinical specimens of extrapulmonary tubercu-
losis was slightly lower, 89.5%. Even so, this was still higher than
most studies, which have used different targets and different
amplification strategies and reported sensitivity values of the
various PCR techniques from 53.8% to 85% [10,18–20].
Apart from its high sensitivity, M RT-PCR provides the results
in just four hours, far less than that required for isolation of Brucella
and M. tuberculosis. The mean time for isolation and identification
of Brucella in a non-blood sample was 5.862.6 days and for M.
tuberculosis it was 21.566.8 and 9.564.4 days, depending on
whether solid or liquid media were used, respectively. Even
assuming that culture is the gold standard for diagnosis of
tuberculosis and that it is the only method enabling a study of
strain sensitivity to treatment, this drastic reduction in diagnostic
delay has important prognostic implications in severe cases, such
as meningitis or vertebral osteomyelitis.
Finally, like other molecular techniques, M RT-PCR is very
versatile, as samples can be stored at 220uC until processing and it
almost completely obviates the need for direct handling of the
pathogens, thus drastically reducing the risk of infection of
laboratory personnel.
One limitation of this study is the reduced sample size and the
diversity of the samples used. Caution should therefore be
exercised with definitive interpretation of the results. Nevertheless,
this is a frequent problem with diseases with a relatively low
incidence and whose form of presentation is very heterogeneous.
In conclusion, under the conditions used here, M RT-PCR
seems to be sensitive and specific, which, coupled with its speed
and versatility, make this technique a very useful tool for the
differential diagnosis between extrapulmonary tuberculosis and
certain focal complications of brucellosis.
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Figure 2. Evaluation of the M RT-PCR assay with clinical samples. A representative set of clinical samples was simultaneously tested for the
BCSP31 gene for Brucella spp (A) and the intergenic region SenX3-RegX3 for M. tuberculosis complex (B). Panel (A) Samples 1, 2 and 3 were pleural
fluid, hepatic abscess and urine, respectively, corresponding to brucellosis patients; sample 7 was CSF, from a patient with S. pneumoniae meningitis;
and samples 4 and 5, positive controls for Brucella and M tuberculosis complex, respectively. Sample 6, negative control. Panel (B). Samples 1, 2 and 3
were lymph node, pericardial tissue and psoas abscess, respectively, corresponding to tuberculosis patients; sample 7 was of vertebral tissue, froma
patient with S. agalatiae pyogenic vertebral osteomyelitis; and samples 4 and 5, positive controls for M. tuberculosis complex and Brucella,
respectively. Sample 6, negative control. Panels (C) and (D). Melting curves of the amplified fragments generated by M RT-PCR. Specific signals for
brucellosis patients and positive controls had melting temperatures of 71.5160.18uC and 71.1260.13uC for tuberculosis patients and positive
controls.
doi:10.1371/journal.pone.0004526.g002
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Figure 3. Double-tube format RT-PCR assay with identical clinical samples to those described in Figure 2. All reactions were optimized
to obtain the best amplification kinetics under the same cycling conditions and reaction mixture compositions, as described in the Methods section.
Panel (A) Clinical samples tested for the BCSP31 gene for Brucella spp. Samples 1, 2 and 3 were pleural fluid, hepatic abscess and urine, respectively,
corresponding to brucellosis patients. Sample 4 was CSF, from a patient with S. pneumoniae meningitis; and samples 5, 6 and 7 were lymph node,
pericardial tissue and psoas abscess, respectively, corresponding to tuberculosis patients, and sample 8 was of vertebral tissue from a patient with S.
agalatiae pyogenic vertebral osteomyelitis. Samples 9 and 10, positive controls for Brucella. Sample 11, negative control. Panel (B). Clinical samples
assayed for the intergenic region SenX3-RegX3 for M. tuberculosis complex, Samples 1 to 8 were identical to those described in panel A. Samples 9
and 10, positive controls for M. tuberculosis complex. Sample 11, negative control. Panels (C) and (D). Melting curves of the amplified fragments
generated by RT-PCR in double-tube format.
doi:10.1371/journal.pone.0004526.g003
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